St. Jude (STJ) Durata Recall Unlikely - Analyst

After getting bludgeoned to death recently on worries about its Durata lead, St. Jude Medical (NYSE: STJ) is seeing signs of life Tuesday as analyst at Piper Jaffray said a Durata recall is highly unlikely.

The firm also sees minimal operational impact from FDA warnings on manufacturing sites and notes a FDA consultant said the corrections are easily addressable.

The firm reiterated an Overweight price target of $48.00 on STJ.

For an analyst ratings summary and ratings history on St. Jude Medical click here. For more ratings news on St. Jude Medical click here.

Shares of St. Jude Medical are up 0.6 percent to $32.04. They are down over 10 percent since the FDA voiced concerns about Durata.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• JPMorgan Starts Arashi Vision Inc (688775:CH) at Neutral
• UBS Downgrades Fonterra Co-operative Group Ltd (FSF:NZ) to Neutral